Company: WHWK
Filing Date: 2025-03-31
Form Type: S-3
Source: 0001193125-25-068942
Chunk: 19

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-03-31
Form: S-3
Chunk 19
---
R1 Capital Fund, L.P. (“Capital Fund”, and together with Qualified Fund, the “EcoR1                                           
 Capital Funds”). EcoR1 Capital, LLC (“EcoR1”) is the general partner of EcoR1 Capital Funds. Oleg Nodelman is the control person of EcoR1 and may be deemed to share dispositive voting power over the shares held by the EcoR1                    
 Capital Funds. Mr. Nodelman and EcoR1 both disclaim beneficial ownership of all shares except to the extent of their pecuniary interest. The address for EcoR1 Capital LLC, the EcoR1 Capital Funds and Oleg Nodelman is 357 Tehama Street #3, San 
 Francisco, CA.                                                                                                                                                                                                                                     |

| 8. | Consists of (i) 1,788,496 shares of common stock purchased in the Private Placement by Invus Public Equities,                                                                                                                            
 L.P. (“Invus PE”), and (ii) 293,504 shares of common stock purchased in the Private Placement by Avicenna Life Sci Master Fund LP (“Avicenna Fund”). Invus Public Equities Advisors, LLC (“Invus PE                                      
 Advisors”), as the general partner of Invus Public Equities, controls Invus Public Equities and, accordingly, may be deemed to beneficially own the shares directly held by Invus Public Equities. Invus Global Management, LLC (“Global 
 Management”), as the managing member of Invus PE Advisors, controls Invus PE Advisors and, accordingly, may be deemed to beneficially own the shares that Invus PE Advisors may be deemed to beneficially own. Siren, L.L.C.             
 (“Siren”), as the managing member of Global                                                                                                                                                                                              |

11

| Management, controls Global Management and, accordingly, may be deemed to beneficially own the shares that Global Management may be deemed to beneficially own. Avicenna Life Sci Master GP LLC                                                         
 (“Avicenna GP”), as the general partner of Avicenna Fund, controls Avicenna Fund and, accordingly, may be deemed to beneficially own the shares directly held by Avicenna Fund. Ulys, L.L.C. (“Ulys”), as the managing                                  
 member of Avicenna GP, controls Avicenna GP and, accordingly, may be deemed to beneficially own the shares that Avicenna GP may be deemed to beneficially own. Mr. Raymond Debbane, as the managing member of Siren